Page 7 - Expanded Access Protocol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Relief Therapeutics Holding AG: Relief Reports 2020 Financial Results and Provides Business Update Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat COVID-19 induced lung injury, today announced its 2020 financial results for the year ended December 31, 2020 and provided a business update. "The past year has been an incredibly productive and rewarding one for all of us at Relief," said Raghuram (Ram) Selvaraju, Chairman of the Board. "We have had an opportunity to make a true difference in fighting ...

Press release content from Accesswire. The AP news staff was not involved in its creation.

Search jobs 20-Jan-2021 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Mergers & Acquisitions 20.01.2021 / 07:00 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLF...

Relief Therapeutics Holding AG: Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil Relief"), a biopharmaceutical company with its lead compound RLF-100 TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH (" AdVita"), a Germany-based, privately held pharmaceutical company developing effective products and strategies to improve the treatment and diagnosis of rare lung diseases, today announced the companies have signed a binding term she...

Search jobs 30-Dec-2020 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study 30.12.2020 / 07:00 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure Geneva, Switzerland and Radnor, Pa, USA, December 30, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company") and NeuroRx, Inc. today announced the c...